Best Direct Primary Care GLP-1 Providers in 2026 — Ranked & Reviewed
Direct Primary Care (DPC) is a membership-based primary-care model that strips out insurance billing and replaces it with a flat monthly fee. A small but growing group of DPC practices have added GLP-1 weight-loss medication to the membership at wholesale or near-wholesale cost — fundamentally different from the DTC marketplace pattern where you pay $300-$500/month for the medication and have no continuous primary-care relationship. The DPC model integrates lab monitoring, medication adjustments, and side-effect management within an ongoing provider relationship, which most clinicians consider the gold standard for chronic-weight-management care. Membership fees typically run $50-$150/month; wholesale GLP-1 then runs $65-$300/month depending on drug, dose, and form. For patients without insurance coverage of brand-name Wegovy/Zepbound, DPC can be the lowest total-cost path to GLP-1 plus comprehensive care.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
2 direct primary care glp-1 providers compared · independently scored against our six-factor methodology.
Quick Picks: Top 2
| # | Provider | Score | |
|---|---|---|---|
| 1 | GoodLife Health | Get started | |
| 2 | Primary Clinic (Direct GLP) | Get started |
Compare the top providers at a glance
Logos, our editorial rating, price, medications, and coverage — the fastest way to narrow the list.
- ★ Editor's Pick
brand-name GLP-1s within ongoing metabolic primary care with quarterly labs, paying for medication separately
From /moCheck pricingCoverageCheck intakeMedicationsSemaglutideTirzepatide - Best Budget
GLP-1 at wholesale cost inside a Direct Primary Care membership
From /mo$85+ required membershipScales with doseCoverage18 statesMedicationsSemaglutideTirzepatide
| Provider | Rating | From /mo | Medications | Coverage | |
|---|---|---|---|---|---|
| ★ Editor's Pick brand-name GLP-1s within ongoing metabolic primary care with quarterly labs, paying for medication separately | Check pricing | SemaglutideTirzepatide | Check intake | Get started → | |
| Best Budget GLP-1 at wholesale cost inside a Direct Primary Care membership | $85+ required membership Scales by dose | SemaglutideTirzepatide | 18 states | Get started → |
Each checked against the provider’s own site.
Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →
Detailed Reviews
GoodLife Health
PartnerBest for: brand-name GLP-1s within ongoing metabolic primary care with quarterly labs, paying for medication separately
GoodLife Health is an online Direct Primary Care membership run by an Arizona clinician-owned practice (not the same company as Good Life Meds). It treats weight with brand-name GLP-1s such as Wegovy and Zepbound alongside hormone and metabolic care. Membership is $299 a month with a lab panel every 90 days included, after a two-month start billed as $598. Medication is not included: the pharmacy or manufacturer program bills you directly, and GoodLife says it adds nothing to that price and never prescribes compounded GLP-1s.
Score Breakdown
Pros
- ✓Membership price is shown before the questionnaire: $598 for the first two months, then $299 a month
- ✓A lab panel every 90 days at Quest is included, covering ApoB, Lp(a), A1c, fasting insulin, thyroid and more
- ✓Prescribes brand-name GLP-1s only, filled through LillyDirect, NovoCare or your insurance, and says it adds nothing to the drug price
- ✓Same membership fee whether you are prescribed semaglutide or tirzepatide, at any dose
- ✓Names its operating companies, their Arizona business IDs, its owner and its physician partner, Beluga Health
- ✓Shows a LegitScript certification seal served from LegitScript's own seal server
- ✓Monthly clinical check-ins, a 30-minute video intake and secure messaging with the care team
- ✓The $598 is refunded in full if a clinician does not accept you into care
Cons
- ✗Medication is not included: brand GLP-1s are billed separately by the pharmacy, and GoodLife does not quote what they cost
- ✗$598 is charged upfront for the first two months and becomes non-refundable once you are accepted
- ✗Labs and a video visit come before any prescription, so starting a GLP-1 typically takes a few weeks
- ✗No refunds for partial months after you cancel
- ✗All seven on-site reviews praise one clinician, and we found no Trustpilot or BBB profile to check them against
- ✗Shows unsourced results graphics, such as a 28 lb loss and 92% more energy, and a co-founder's own Wegovy results as proof
- ✗Mentions a 'partner pharmacy network' without naming the pharmacies
- ✗No phone support; non-members can only email, and the help chat requires a member login
Primary Clinic (Direct GLP)
Best for: GLP-1 at wholesale cost inside a Direct Primary Care membership
Primary Clinic (Direct GLP) is a Direct Primary Care membership rather than the usual direct-to-consumer GLP-1 marketplace. For $89/mo members get unlimited primary care, direct text access, same-day virtual visits and routine labs, then buy compounded 503A GLP-1s at wholesale cost with nothing added: semaglutide from $85/mo, tirzepatide from $133/mo. Currently available in 10 states, with medication monitoring built into an ongoing care relationship.
Score Breakdown
Pros
- ✓Direct Primary Care model integrates GLP-1 with continuous primary care, unlike most direct-to-consumer platforms
- ✓GLP-1 at wholesale cost with nothing added: semaglutide from $85/mo, tirzepatide from $133/mo (members only)
- ✓Unlimited primary care visits, direct text access, and same-day care bundled in the $89/mo membership
- ✓Routine labs and thousands of medications included in membership, so no surprise bills
- ✓Per-dose pricing shown publicly for all 8 dose tiers of both semaglutide and tirzepatide
- ✓Publishes the FDA 503A compounded-medication disclaimer
Cons
- ✗18 states only (AZ, CO, DC, FL, GA, IA, ID, KS, MT, NE, NM, NV, NY, OK, OR, UT, VA, WA), which is limited vs 50-state platforms
- ✗Membership required to access wholesale pricing: $89/mo adds ~$1,068/yr in fixed cost
- ✗503A pharmacy partners not named
- ✗LegitScript certification not mentioned on the site
- ✗Medical director and corporate legal entity not disclosed
- ✗Compounded only, with no brand-name Wegovy, Ozempic, Mounjaro, or Zepbound
- ✗Refund policy not disclosed publicly
How we rank & what counts as “legit”
Every provider in this ranking is scored against our published six-factor rubric[1] — value, effectiveness, user experience, trust & safety, accessibility, and support.
Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are separately FDA-approved under their own NDA numbers[4][5]. Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial[6], and for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) from SURMOUNT-1[7]; the SURMOUNT-5 head-to-head published in 2025 compared the two directly[8].
Insurance coverage for anti-obesity medications varies widely by state Medicaid program and commercial plan[9][10]. Compounded and brand-name GLP-1s are generally FSA/HSA eligible with a prescription under IRS Publication 502[11].
Frequently Asked Questions
Sources & methodology (as of November 2026)
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.